Novartis announces early clinical data for unique KRASG12C inhibitor at American Association for Cancer Research annual meeting

PRESS RELEASE Corporate Announcements


Novartis AG

Basel, April 11, 2022 — Novartis today announced promising clinical data for JDQ443, an investigational selective, covalent, and orally bioavailable KRASG12C inhibitor at the annual meeting of American Association for Cancer Research (AACR). Comprehensive information on the discovery of JDQ443 is also included in a poster being presented on Wednesday 13th April with further details published in the journal Cancer Discovery.

Related News

ASEC Frontier (Thailand) Co., Ltd

Address : 1 Empire Tower, Unit 1509,1710

15th,17th floor South Sathorn road Yannawa

Sathorn Bangkok, Thailand 10120

Tel : +662-118-0873

Email :

Website :


Contact Us